C5 and hemolytic-uremic syndrome: By unraveling the role of alternative pathway dysregulation in atypical HUS [172,173,174,175,176,177], investigators have initiated the use of eculizumab, a terminal C5 inhibitor, which is now established as a mainstay in the management of patients with atypical HUS [178,179,180,181,182].